Related Experiment Video
Updated: Sep 12, 2025

Isolation of Human Primary Valve Cells for In vitro Disease Modeling
Published on: April 16, 2021
Investigating the epigenetic basis for aortic aneurysm risk in patients with bicuspid aortic valve disease
Abdul Badran1,2, Christopher J Goulden3, Amer Harky4
1Wessex Department of Cardiothoracic Surgery, University Hospital Southampton, UK.
Abstract:
BackgroundBicuspid aortic valve (BAV) is a common congenital cardiac malformation associated with significant morbidity, including aortic dissection and thoracic aortic aneurysms. The mechanisms underlying BAV-associated aortopathy are unknown. We aimed to identify methylation profiles in BAV patients with aortopathy and investigate associated genetic pathways.MethodsTissue samples from the ascending aorta were obtained from BAV patients undergoing thoracic aortic surgery. DNA methylation profiles were measured using Illumina human 850K array. Probe methylation associations were reviewed, and a regression model assessed associations with aortic dimension.ResultsEight patients were recruited from University Hospital Southampton. Analysis revealed HEATR5A, PHLDB2, ADAMTS17, BID, and TLK1 as significantly associated genes. These genes were implicated in aortic wall remodelling through novel mechanisms identified by an unbiased, integrated epigenomic approach.ConclusionsThis study provides novel insights into epigenetic regulation in BAV-associated aortopathy. Identified genes, including HEATR5A, PHLDB2, ADAMTS17, BID, and TLK1, may contribute to aortic disease in BAV patients. Further research is needed to elucidate their mechanisms and therapeutic potential. Our findings improve understanding of the molecular basis of BAV-associated aortopathy and may inform future diagnostic and therapeutic strategies.
More Related Videos
Related Concept Videos
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation I: Introduction
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Aneurysm I: Introduction
Aortic Regurgitation III: Medical Management

